Abreva and Gallbladder attack - a phase IV clinical study of FDA data

Summary:

We study 21,172 people who take Abreva (docosanol) or have Gallbladder attack. No report of Gallbladder attack is found in people who take Abreva.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Abreva?

Abreva has active ingredients of docosanol. It is often used in herpes labialis (oral herpes simplex). eHealthMe is studying from 17,071 Abreva users. Check the latest studies of Abreva.

What is Gallbladder Attack?

Gallbladder attack (gallstones, gallbladder disease and gallbladder pain) is found to be associated with 565 drugs and 995 conditions by eHealthMe. Check the latest studies of Gallbladder attack.

On Jun, 18, 2026

No report is found.

Do you take Abreva and have Gallbladder attack?

- Check whether Gallbladder attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abreva:

Abreva (17,071 reports)

Browse all side effects of Abreva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gallbladder attack:

Gallbladder attack

Browse all the conditions that are associated with Gallbladder attack:

Gallbladder attack

How the study uses the data?

The study uses data from the FDA. It is based on docosanol (the active ingredients of Abreva) and Abreva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.